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Abstract 
The research into the use of small molecules as drugs continues to be a key driver in the development 
of molecular databases, computer-aided drug design software and collaborative platforms. The 
evolution of computational approaches is driven by the essential criteria that a drug molecule has to 
fulfil, from the affinity to targets to minimal side effects while having adequate ADME properties. A 
combination of ligand- and structure-based drug development approaches are already used to obtain 
consensus predictions of small molecule activities and their off-target interactions. Further integration 
of these methods into easy to use workflows informed by systems biology could realise the full 
potential of available data in the drug discovery and reduce the attrition of drug candidates. 
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Body of the text 
Small molecules as drugs and drug candidates continue to be of interest for pharmaceutical industry 
[1,2] despite the current backdrop of a global pipeline for new medicines that is running dry across a 
range of therapeutic areas (see  e.g.[3,4]) and a trend towards complex biologics as the next generation 
of therapeutics, particularly for inflammatory diseases and cancers [5–7]. It could be assumed by 
world-weary pharmaceutical scientists that the days when small molecules, broadly defined as  
compounds which adhere to Lipinski’s rules of five[8], were the preferred starting point in drug 
discovery projects are coming to an end.  The high failure rates in the later stages of small molecule 
drug discovery projects, caused by a lack of efficacy and problems with safety profiles [9]  give 
significant cause for concern in the pharmaceutical industry. This has led big pharma to review their 
discovery pipeline strategies and develop initiatives – such as AstraZeneca’s 6 R’s framework [10] – to 
ensure that potential liabilities are removed early in the process. 
It would seem counterintuitive that in an age where information is increasingly prevalent and 
accessible, the failure rate for small molecules at the later stages of drug development projects is still 
so stubbornly high. Whilst it can be argued that some efficacy and toxicological data relating to small 
molecules is proprietary, and the inability to access such information can result in unsuitable 
molecules being progressed through the drug discovery pipeline, it is likely this number is small. If we, 
as a scientific community, accept this statement it implies that we are not learning enough from past 
mistakes. It is possible that a number of current projects are progressing molecules which are destined 
to fail, and that this future failure was predictable in the early stages of the project via a thorough and 
systematic interrogation of the existing and accessible knowledge base. This boils down to the root of 
the problem being a problem of big data.  
The information available for the use in drug discovery processes can be characterized by the “5 Vs” 
i.e. volume – typically big data concerns datasets; variety – the different nature of the types and forms 
in which data is acquired; velocity – the rate at which new data relating to a topic is becoming 
available; variability –inconsistencies with how data is reported, which may hinder subsequent 
analysis; and veracity – whether the data that is under investigation can be trusted to be accurate.[11] 
To be successful in identifying novel compounds in the future, it is imperative to overcome challenges 
of 5 Vs and understand,  harness and progress from the wealth of information that is currently 
available. This colossal task is reliant upon the development of sophisticated in-silico systems to help 
capture, store, curate, analyse and exploit the vast amount of data relating to small molecules. This 
data can be broadly categorised into non- clinical data i.e. information pertaining to the structure of 
the molecule, its physicochemical properties and the information from in vitro and in vivo animal 
experiments to establish preliminary biological activity and toxicology profiles, and clinical data i.e. 
data relating to efficacy and toxicology of molecules as a result of clinical trials. Arguably, the greatest 
gains are to be made by analysing the data at the non-clinical development stage, as identifying 
patterns at this point in the process, which will ultimately result in failure in clinical trials will help to 
prioritise resource. The challenges to achieving this arise from the storage, extraction and analysis of 
the appropriate data. 
The physical computing resource for storing, managing and, crucially, analysing the vast amount of 
freely available small-molecule data is immense, and in the recent past would have proved a financial 
barrier to a global, information-rich approach to drug discovery.  However, the advent of cloud 
computing, whereby data is stored, managed and processed on remotely networked servers, provides 
a credible solution to this problem. Cloud computing has already been successfully used in small 
molecule drug discovery experiments for computer memory intensive activities such as de novo drug 
design and virtual screening[12–14] by allowing the combined processing power of networked 
  
computers to perform complex simulations in an acceptable timeframe, but risks and perception of 
risk with respect to issues such as information security, data location and disaster recovery[15] 
continue to limit the widespread adoption of cloud computing, particularly in drug discovery settings 
where the potential financial rewards for addressing unmet clinical needs can be substantial. 
This is not to say that the scientific community guards its data jealously; nothing could be further from 
the truth. Simple web-browser searches quickly identify a dizzying array of small molecule databases, 
which contain vast amounts of information that can be harnessed for drug discovery projects. These 
databases range from large repositories containing top-level information across a number of different 
areas (e.g. physical, toxicological and spectral properties of small molecules) such as Zinc[16] 
ChemSpider[17] and PubChem [18] through to those that deal in more detail with compounds that 
are known or predicted to demonstrate biological activity (CheBI[19], ChemBL[20] DrugBank[21]), 
those that focus on drug targets and the molecules known to act on them (IUPHAR[22]) and those that 
consider the metabolites of compounds and the implications of these on patient safety (e.g. Urine 
Metabolome[23], IMDB Toxin[24]). All these resources contain information, which would reliably 
inform drug development projects but there are two big data problems, volume and reliability of data, 
that present a barrier to easy harvesting and applying this information. Although each of the database 
providers mentioned have developed procedures for automated data acquisition and validation, there 
is a need for manual inspection of retrieved data due to duplication of data entries and possible 
variability of results of assays from different research groups.  Although a suite of sophisticated web 
services for these databases is available, which scientists can use to interrogate their databases, it can 
be difficult for users to extract the exact information they need for their project[25], and another 
problem of big data – that of variability with respect to how data is stored in each individual repository 
– can require researchers to spend a lot of time training to become experts in using a number of 
different web services which again prevent them accessing all relevant information prior to embarking 
on their project. One way of overcoming these challenges is via the judicious use of web  scraping. 
In essence, web scraping (also known as web harvesting) is the copying of information from the web 
to a local repository, usually with the intention of subsequently manipulating and analysing this 
information. Although a person manually copying and pasting information from the web into a local 
database is doing webscraping, the term is more usually associated with the automated data 
collection of ‘bots’ or ‘web  crawlers’, small pieces of programming code which are designed to harvest 
and deposit relevant pieces of information with minimal human intervention. Such activities were 
initially computationally complex and required expert knowledge of the web and scripting languages. 
However, the development of freely available desktop technologies such as iRobotsoft[26] means that 
this technique for gathering data is now available to novice, as well as expert, users. 
Despite being one of the oldest technologies for extracting data from the internet, web scraping can 
prove invaluable where web services provided by database moderators do not meet the data capture 
needs of the user, and could prove invaluable in collating disparate data from the multitude of small 
molecule databases available prior to embarking on a drug discovery experiment. It is not, however, 
without its limitations. In order for their databases to be mined by bots the curators need to provide 
access, which is not always readily forthcoming given concerns over malicious hacking and information 
security. In addition legal jurisdictions with respect to where the data is stored can prove problematic 
as different thresholds exist in different parts of the world[27]. These limitations have not completely 
stymied recent drug discovery initiatives which have combined web-scraping with data-mining 
technologies to ensure that the latest and most relevant information related to small molecule drug 
discovery from a range of different sources is being considered at the implementation stage of drug 
discovery projects (see e.g [28]). 
  
Data mining, sometimes used synonymously with machine learning, is the autonomous analysis of 
large-scale datasets to generate new information, and will be at the heart of this big data era of small 
molecule drug discovery. Networked computers processing information (for example the information 
extracted via web-scraping) will be used to identify previously obfuscated patterns that can directly 
input into rational drug design and development[29]. This technique is already proving beneficial to 
investigations into drug repurposing, a relatively low-risk strategy where small molecules that are 
known to have therapeutic benefits and acceptable safety profiles are investigated to see if they can 
be applied to other conditions by exploiting drug repurposing databases such as the NCGC 
Pharmaceutical Collection[30]. A number of drug repurposing studies have already been published to 
demonstrate the potential of machine learning for exploiting information to identify novel molecular 
disease targets[31] and repurpose existing medications for the treatment of a range of conditions 
including lupus[32], neurodegenerative disorders[33] and tuberculosis[34]. As it becomes easier to 
collate and analyse more data it is expected that this technology can also make significant in-roads 
into combatting orphan diseases, which although rare still affect up to 350 million people 
worldwide[35].     
The information about small molecules and their properties should be complemented with 
information that is available about biological targets. The probability of discovering a next blockbuster 
drug through serendipity has become negligible and various in silico screening approaches as well as 
computer-aided molecule design methods are being developed. The availability of structural 
information of biomolecules complexed with small molecules with potential bioactivity in Protein Data 
Bank (PDB) [36] and PDB-REDO [37] is increasing year-on-year. There are currently over 98k models 
of biomolecules in a complex with a ligand available for the download and possible use in the drug 
discovery process. One of the most common uses of these target structures is to evaluate a potential 
binding mode of a small molecule through molecular docking (see e.g. [38]), if the binding sites for 
those structures are known. The trend in increase of number of available structures in the PDB is 
considerably higher than the number of publications in the Scopus database that have “docking” and 
“pdb” words mentioned anywhere in the text of the publications. This is most likely due to two factors, 
the released structures are either refined structures of previously released complexes with different 
ligands or published structures are not druggable targets.  The in silico evaluation of protein 
druggability can be achieved using protein structural information, their known interactions with FDA 
approved drugs and knowledge of the human genome [39], albeit this approach provides only 
information on human targets and neglecting drugs that act on proteins expressed in other organisms.   
Since the researchers are often faced with the lack of the structural information on targets of interest 
alternative strategies are employed, such as homology modelling to use existing structures to obtain 
structural information about the same targets from different organisms or structures of novel targets. 
In this way increased number of targets provides additional opportunities to apply docking in an 
attempt to find therapeutic agents against a wider range of diseases, resulting in almost two-fold 
higher number of publications that use homology models when compared to those where the docking 
is carried against a structure from the PDB. As a consequence of the issues mentioned, the information 
about targets is less suited for automation of the docking process. Furthermore, most of the docking 
protocols require careful examination of the available target structure which includes pre-processing 
of models obtained by either x-ray crystallography and NMR spectroscopy.  However, web services 
are being developed, such as SwissDock, that are providing an opportunity to carry out docking against 
already prepared targets with well-defined binding sites [40]. Albeit this provides an easy access to 
selected targets and opportunity for direct comparison of the docking results from different research 
groups as the preparation of targets, scoring functions and algorithms used for docking are always the 
same, the usefulness of this service is limited by the number of proteins available in such databases. 
  
Similarly, the other web services that provide collated information on proteins important in drug 
discovery, Potential Drug Target Database (PDTD) [41] and Therapeutic Target Database (TDD) [42], 
have a potential to be useful resources in the drug discovery efforts. However the lack of updates or 
information on the latest updates is impeding their future use. 
Significant progress in improving the relevance of docking results is being made by taking into 
consideration the flexibility of targets [43] and docking with explicit hydration[44], and these efforts 
are further enhanced by the development of computational approaches to elucidate modulation of 
target via potential allosteric binding site [45]. In certain cases, biological activity and the binding 
affinity cannot be attributed to binding to active and/or allosteric sites. In those cases, the affinity 
studies should be carried by molecular docking against the whole protein/target surface to obtain a 
working hypothesis [46]. To ensure that the theoretical  studies of interactions between protein and 
a small molecule  provide the most reliable results the docking results against known binding site 
should be complemented by docking against the whole surface of the target using methods similar to 
those in the BINDSURF approach [47] and implementation of multi-objective strategies for combining 
scoring functions [48]. The future of the docking software development should be aiming to 
incorporate the above enhancements into the process for the hit identification as well as in lead 
optimization efforts when docking ligands against target databases. 
Docking against multiple targets is already employed in target fishing by using reverse docking. This 
approach is particularly useful if biological activities of sets of molecules determined in cell-based 
assays are known, but without knowledge of the target protein. The great promise of this approach 
was demonstrated by predicting targets for 4OH-tamoxifen and vitamin E, where 50% of 
computationally predicted targets were implicated in the binding of these two molecules [49]. This 
concept of “target fishing” was developed further via developing a PDTD with the defined binding sites 
of proteins known to be targets for small molecule therapeutics. The improved algorithms and scoring 
functions led to the improvement  of the target identification results for 4H-tamoxifen and vitamin E 
[50]. Although promising, this approach has not been utilized fully in most disease areas, the 
TarFisDock was mainly used in studies to explain activities either of sets of sets of molecules that may 
have multiple targets [51] or of components of plant extracts  [52].. This is mainly due to a complexity 
of the results obtained, as well as the lack of direct correlation between observed biological activities 
and corresponding binding affinities to a single possible target. This could be a result of ligands with 
the activity having affinity for several targets and a possible interplay of cellular pathways affected by 
these interactions. Therefore, the target selection has to be informed by knowledge-based 
approaches and using a target pool relevant to the disease of interest [51,53], and further 
complemented by systems biology computational analysis [54] and network biology [55]. 
It is apparent that target fishing through molecular docking approaches has some drawbacks, as the 
activities of small molecules depend on their molecular properties as well as on the target availability. 
Therefore, other approaches are being developed to address the important issue of target 
identification that often arises from high throughput screening (HTS) or developing of libraries of 
analogues. The drug target interactions can be predicted based on the structures of ligands through 
the comparison to the information derived from known three dimensional structures of protein-drug 
complexes. An open web server, TargetNet, utilizes naïve Bayes approach in SAR models to evaluate 
possible affinity of ligands for 623 human proteins [56]. While the ligands are represented as 
molecular fingerprints for TargetNet to evaluate molecular similarity, the  use of 2D structures and 
fingerprints is a simplification and can lead to biased results, as the outcomes of searches can depend 
on the methods used to evaluate similarity [57]. This type of a limitation was purposely addressed 
when developing the PolyPharmacology Browser  (PPB), where sets of ligands binding to the same 
  
target are used to develop a consensus voting scheme where six different fingerprints and four fused 
fingerprints to evaluate similarity of a query molecule to ligands present in ChEMBL database. 
Moreover, the use of molecular similarity of ligands in quest for target responsible for activity can be 
expanded by evaluation of their 3D shape and surface feature similarity in addition to using 2D 
similarity as criteria to predict a possible target. The Chemmapper  website [58] allows comparison of 
a molecular structure of a query molecule to a diverse sets of ligands with known binding in the PDB 
(7072 structures) and KEGG (5928 structures) datasets, as well as to ligands present in big data 
bioactivity databases (DrugBank, ChEMBL and BindingDB).  However, the results of 2D and 3D 
similarity comparisons are obtained and have to be analysed separately. 
An additional dimension to target identification was introduced by combining 2D and 3D similarity 
measures between a query molecule and identified ligands as implemented in the 
SwissTargetPrediction website [59].  Furthermore, the SuperPred webserver takes into consideration  
2D, fragment and 3D molecular similarity of a query molecule to all ligands that are associated with 
the targets in the database [60]. The applicability domain of these two webservers is possibly larger 
compared to previously mentioned services, as their target databases contain proteins that are not 
only human but also from other mammals. 
However, the above mentioned ligand-based approach to target identification that uses direct 
comparison of a query structure to a single ligand from the binding databases may not provide a 
comprehensive overview of the potential interactions that can occur. The development of a 
pharmacophore approach can take into consideration features in query molecules that should be 
present for favourable binding to occur. The website Pharmmapper provides a platform for a reverse 
pharmacophore mapping approach [61,62], that uses over 23k protein structures from the PDB to 
develop druggable and ligandable pharmacophores in relation to 450 indications and 4800 molecular 
functions related to these protein structures.  Currently, the number of publications citing  
Pharmmapper in the Scopus search outnumbers publications involving the  other above-mentioned 
approaches, most likely due to the inclusion of targets that are non- mammalian such as bacterial 
targets being important in a search for therapeutic agents to treat multidrug resistant strains. These 
are particularly useful features of the Pharmmapper service in addition to providing the information 
related to function of targets and relevant indications. However, pharmacophore models that are 
generated for this server are based on a single structure for each target protein. This results in the 
multiple occurrence of the same protein in the resulting list of targets for a query molecule. An 
opportunity to consider multiple experimentally determined structures for target proteins is 
overlooked, as that could introduce some elements of the protein flexibility in target identification 
and diversify type of ligands that could fit into such pharmacophores.  
There are other platforms that deal with the use of big data  in target identification for small molecules 
that show activity in cell-based and whole organism assays (see [57] for a comprehensive list). 
However, all of those approaches have their limitations leading to an uncertainty  of target prediction 
for each query molecule. This may be overcome by merging the best features of already developed 
approaches into a single platform and proposing a census scoring of each solution obtained by 
different methods. 
It is interesting that these relatively recent efforts in developing methods for target fishing did not 
result in the expected progress of identifying targets for molecules with known activity and the 
number of publications does not reflect the promise that these methods offer. There are some 
examples of useful applications that arose from application of one or a combination of several 
methods that led to, for example, the discovery and experimental validation of novel mechanisms of 
inhibition in Magnaporthe oryzae by a chalcone-based inhibitor [63] and identification of ten 
  
phytochemicals  from Rhazya stricta that may have good anticancer activities [64].  There are also 
some examples where these  services enabled scaffold hopping in identification of novel inhibitors for 
treatment of type 2 diabetes [65] and small lung cancer [66]. The experimental validation of predicted 
targets is becoming one of the most important criteria for consideration of manuscripts, which is not 
always an easy undertaking, thus the number of studies that report successful target identification is 
relatively low.  
Despite the discouraging outcome for discovery of hits and development of lead molecules, the 
applications of the methods described above and similar ones have boomed in three other fields: 
evaluating polypharmacology of small molecules, off-target interactions prediction and drug 
repurposing.  
The initial efforts in predicting the side effects of small molecules was via evaluation of their affinity 
towards protein structures using the inverse docking procedure [67]. This has led to development of 
a number of webservers employing structure-based approaches.  Virtualtoxlab tool is one of the first 
server implementations that provided prediction of toxic potential for small molecules via evaluating 
their interactions with 16 proteins. This set of proteins are known or suspected to trigger adverse 
effects and include 10 nuclear hormone receptors (NHR).  These predictions are made by a 
combination of flexible docking with multi-dimensional QSAR [68,69]. It may appear that such 
predictions are not important as the comprehensive in vitro study of 615 drugs did not find a 
significant number of drugs that interact with the NHR. The most likely reason for absence of 
interactions of drugs with NHR is that drug candidates with a potential to exert such interactions were 
discontinued during the drug development process. Although these experiments did not indicate 
problems related to NSAID toxicity, Virtualtoxlab results revealed that diclofenac and celecoxib may 
have affinity for thyroid hormone receptor . This receptor is implicated in hypothyroidism associated 
with increased heart muscle stiffness and therefore inhibition may lead to an increased risk of 
myocardial infarction. These in silico findings  were confirmed by ex vivo studies, indicating the 
importance of prediction results [70], especially if these are used in early drug discovery and 
development stages. Opensource developments in this areas are also prominent, where a website 
service “Endocrine Disruptome” provides a similar prediction of small molecule affinities to 12 NHRs 
[71], allowing toxicity predictions in resource-challenged environments. Moreover, their docking 
interface for target systems (DoTS) is freely available for implementation on secure servers, thus 
addressing potential intellectual property issues that may arise if publicly available servers are used. 
While significant progress has been made in utilizing in silico methods to predict drug-target 
interactions (see e.g. [72]) and enable drug repurposing (see e.g. [73], utilising not only standard 
methods and ideas, but also innovative concepts, approaches and algorithms, there are intrinsic 
problems that are related to how the research in this area is funded and how these efforts are 
rewarded. Whilst the pharmaceutical industry is engaged in data sharing and there are excellent 
examples of developing collaborative platforms for opensource drug discovery [34], their need to 
protect their intellectual property and not share all the data and software applications  is 
understandable. However, due to the lack of appropriate funding, the efforts of the academic 
community often result in projects that are short-lived delivering sometimes ingenious software 
solutions that are frequently not finished and/or difficult to integrate into other relevant software 
platforms as the file formats and data storage are not standardized. More often than not, as a drive 
to meet criteria for academic promotions and to achieve quick wins, software solutions or web 
services are developed that appear redundant and do not significantly contribute to furthering the 
progress in the field. Furthermore, the efforts in developing collaborative drug discovery projects 
appear not to be unified as the researchers have to make a choice where to direct their efforts when 
  
there many platforms available, e.g. Open PHACTS [74], Online chemical modelling environment [75], 
Collaborative Drug Discovery Vault [76], in addition to platforms dedicated to specific therapeutic 
areas such as SysBorg 2.0 for open source  drug discovery platform to fight tubercolosis  [77] . 
Future perspectives 
In order to have a true impact on small-molecule drug discovery projects, the acquisition and 
processing of pertinent big data will need to be standardized and automated. However, a dichotomy 
exists whereby such automation will need to be generalizable enough to broadly apply to any drug 
discovery project whilst also being customisable enough to address the nuances of each therapeutic 
target including not only proteins but also oligonucleotides and other validated druggable targets.  
Additionally, these automated analysis frameworks would need to be accessible to non-experts in 
order to ensure that barriers to their adoption don’t exist.  
As such, modular workflow interfaces seem set to play (an even bigger) role in the near future. 
Although competitors are emerging into this market all the time, there are two main pieces of 
software which have influenced drug discovery over the past twenty years, namely the proprietary 
Pipeline Pilot[78] which was launched in 1999 and the Open Source KNIME[79] which followed in 
2004. Both of these tools allow users to build general architectures from a library of pre-designed 
modules in a “drag and drop” style to facilitate the automated processing and filtering of data. They 
do this whilst retaining sufficient fine control to allow these architectures to easily become custom-
tailored by giving users the ability to modify threshold values for parameters in each of the modules 
to suit the needs of their project.  
These architectures can incorporate well-established models for predicting not only potential activity 
of small molecules but also physicochemical and toxicological properties such as aqueous 
solubility[80–82], plasma-protein binding[83], blood-brain-barrier permeation[84–86] cytochrome 
P450 isoform specificity[87]  [88] and off-target interactions [50,56–62] in order to remove potential 
liabilities at an early stage of the process. It is desirable that in the future calculated properties could 
be compared against a database of experimental values for such properties harvested from the web 
to highlight limitations of any model and guard against identifying false negatives as part of the 
screening process. It is also possible that the workflow could then be extended to use machine learning 
to address the weaknesses of a model, based on the outcome of these comparisons and automatically 
build, test and validate iterative models based on the information it receives  [89]. Although we have 
not reached this stage yet, there are again a significant number of publications in the scientific 
literature, which show the positive impact of workflow interfaces in a diverse range of therapeutic 
areas including the identification of molecules with the potential to treat cancer [90][91,92], and those 
with potential to act as anti-inflammatory compounds [93]. Given the scalability of such interfaces, it 
does not seem unreasonable to expect their prominence to grow in small molecule drug development 
in response to the challenges and opportunities presented by big data.  
 
 
  
  
Executive summary 
Small molecules continue to attract the interest of pharmaceutical companies and academic 
research groups as drugs and drug candidates. 
Increased availability of information on molecular properties of small molecules, their biological 
activities and targets drive the development of methods for processing big data.  
The optimal use of small molecule information can be achieved in conjunction with the structural 
information available on the biological targets. 
Publicly available web servers can be used to predict potential targets for small molecules and off-
target interactions via a combination of ligand-based and structure-based methods.   
Standardization of the data storage in the databases and incorporation of well-established methods 
for prediction of activities, molecular properties, side effects and network biology into easy-to-use 
workflows can provide a basis for the next paradigm in drug discovery. 
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